Company news

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A (SSE:600276) news

Every Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A press release and news update in one place — announcements, filings coverage, and company updates for...

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A (SSE:600276) news

Press releases & updates

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Orphan Drug Designation from the US FDA

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Drug Registration Approval

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in A-share Repurchase

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Notice of Approval for Drug Clinical Trial

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Inclusion of Key Pharmaceutical Products of the Company in the National Essent...

Jiangsu Hengrui Pharmaceuticals : Hengrui Pharma Announces Positive Topline Data from Two Phase 3 Clinical Trials of Oral Small Molecule ...

"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Incl...

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Announcement on Obtaining Drug Registration Approval

Announcement on Withdrawal of Drug Registration Application

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA

Announcement on Obtaining Notice of Approval for Drug Clinical Trial

Announcement on Progress in A-share Repurchase

Announcement on Convening the Q1 2026 Performance Briefing

Announcement on Implementation of Dividend Distribution for 2025

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Im...

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

Announcement on Inclusion of Drug in Breakthrough Therapy Designation List

Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors

Announcement on Completion of Unlocking the Lockup Period of Employee Stock Ownership Plan

Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing

Hengrui Pharma Announces Strong 2025 Annual Results

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization

Announcement on Election of Employee Representative Directors for the 10th Board of Directors

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, ...

Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a F...

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Resolutions of the 15th Meeting of the 9th Board of Supervisors

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist H...

Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in S...

Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893

Jiangsu Hengrui Medicine : Hengrui Pharma Has Announced its Record-breaking First-half 2025 Results

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4...

Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agoni...

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Assoc...

Jiangsu Hengrui Medicine : Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023